Literature DB >> 23007526

The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma.

Yan Li1, Wanqi Zhou, Langli Wei, Jing Jin, Ke Tang, Chao Li, Bin Tean Teh, Xiaoguang Chen.   

Abstract

Aurora kinases have been shown to be involved in the regulation of the cell cycle and are related to tumor progression. This suggests the possibility that they can serve as new anticancer targets for tumor treatment. However, the important roles that Aurora kinases and their signaling pathway play in renal cell carcinoma (RCC) are not fully understood and addressed to date. In this study, we aimed to address these questions. We observed that downregulation of Aurora kinases induced by AurA miRNA, AurB miRNA or VX680 could inhibit proliferation and metastasis, induce G2/M phase arrest in clear cell renal cell carcinoma cells and exert antitumor activity in an SN12C xenograft model. We also show that either silencing of Aurora kinases or treating the cells with VX680 could downregulate the expression of cdc25c and cyclin B/cdc2, upregulate the expression of p-cdc2 (Tyr15) via blocking the activity of ERK. All these changes may contribute to inhibition of proliferation, metastasis and G2/M arrest in ccRCC. In summary, we proved that both Aurora kinases A and B are key elements of tumor growth regulation, and inhibition of Aurora kinases may contribute to blocking ccRCC progression. We conclude that Aurora kinases could be potential therapeutic targets in the management of renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007526     DOI: 10.3892/ijo.2012.1633

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.

Authors:  Sumanta K Pal; Miaoling He; Tommy Tong; Huiqing Wu; Xueli Liu; Clayton Lau; Jin-Hui Wang; Charles Warden; Xiwei Wu; Sabina Signoretti; Toni K Choueiri; Jose A Karam; Jeremy O Jones
Journal:  Mol Cancer Res       Date:  2014-09-02       Impact factor: 5.852

2.  Knockdown of Aurora-B inhibits the growth of non-small cell lung cancer A549 cells.

Authors:  Jing Jing Yu; Long Dian Zhou; Tian Tian Zhao; Wei Bai; Jing Zhou; Wei Zhang
Journal:  Oncol Lett       Date:  2015-07-08       Impact factor: 2.967

3.  β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.

Authors:  Ruhee Dere; Ashley Lyn Perkins; Tasneem Bawa-Khalfe; Darius Jonasch; Cheryl Lyn Walker
Journal:  J Am Soc Nephrol       Date:  2014-10-13       Impact factor: 10.121

4.  Let-7g reverses malignant phenotype of osteosarcoma cells by targeting Aurora-B.

Authors:  Jia Ming Liu; Xin Hua Long; Guo Mei Zhang; Yang Zhou; Xuan Yin Chen; Shan Hu Huang; Zhi Li Liu; Zhi Hong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

5.  RNA interference-mediated knockdown of Aurora-B alters the metastatic behavior of A549 cells via modulation of the phosphoinositide 3-kinase/Akt signaling pathway.

Authors:  Long Dian Zhou; Xu Xiong; Xin Hua Long; Zhi Li Liu; Shan Hu Huang; Wei Zhang
Journal:  Oncol Lett       Date:  2014-08-20       Impact factor: 2.967

6.  RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).

Authors:  Sofie Martens; Vera Goossens; Lars Devisscher; Sam Hofmans; Polien Claeys; Marnik Vuylsteke; Nozomi Takahashi; Koen Augustyns; Peter Vandenabeele
Journal:  Cell Death Dis       Date:  2018-02-12       Impact factor: 8.469

7.  Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.

Authors:  Yan Li; Wanqi Zhou; Ke Tang; Xiaoguang Chen; Zhiqiang Feng; Jindong Chen
Journal:  Oncol Rep       Date:  2017-08-14       Impact factor: 3.906

8.  Inhibition of Aurora-B suppresses osteosarcoma cell migration and invasion.

Authors:  Xiao Ping Zhu; Zhi Li Liu; Ai Fen Peng; Yun Fei Zhou; Xin Hua Long; Qing Feng Luo; Shan Hu Huang; Yong Shu
Journal:  Exp Ther Med       Date:  2014-01-20       Impact factor: 2.447

9.  Quantifying critical states of complex diseases using single-sample dynamic network biomarkers.

Authors:  Xiaoping Liu; Xiao Chang; Rui Liu; Xiangtian Yu; Luonan Chen; Kazuyuki Aihara
Journal:  PLoS Comput Biol       Date:  2017-07-05       Impact factor: 4.475

10.  ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m6A-dependent manner.

Authors:  Xiaolei Zhang; Feng Wang; Zijie Wang; Xiao Yang; Hao Yu; Shuhui Si; Jiancheng Lu; Zijian Zhou; Qiang Lu; Zengjun Wang; Haiwei Yang
Journal:  Ann Transl Med       Date:  2020-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.